1 1

Cited 0 times in

Cited 0 times in

Secukinumab Efficacy Predictors in Korean Hidradenitis Suppurativa: A 48-Week Clinical Trial Analysis

DC Field Value Language
dc.contributor.authorHa Nguyen, Ngoc-
dc.contributor.authorLee, Sang Gyu-
dc.contributor.authorHam, Seoyoon-
dc.contributor.authorLee, Ju Hee-
dc.contributor.authorLee, Young In-
dc.date.accessioned2025-12-24T07:09:44Z-
dc.date.available2025-12-24T07:09:44Z-
dc.date.created2025-12-11-
dc.date.issued2025-10-
dc.identifier.issn2160-9381-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/209638-
dc.description.abstractBackground: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels commonly occurring in body folds. The IL-17A inhibitor, secukinumab, has shown efficacy in reducing HS lesions in clinical studies, but data on epidemiologic and patient-specific factors influencing response remain limited. Objectives: To assess how baseline disease severity, treatment initiation delay, and prior biologics exposure influence clinical response to secukinumab and patterns of antibiotic use. Materials and Methods: This 48-week real-world prospective trial enrolled 10 Korean patients with moderate-to-severe HS. Patients received secukinumab 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every two weeks. Outcomes included Hidradenitis Suppurativa Clinical Response (HiSCR), a 55% reduction in the International HS Severity Score System (IHS4-55), mean change in abscesses and inflammatory nodules, a >= 30% reduction in pain score on a numeric rating scale (NRS30), and duration of concomitant antibiotic use. Results: At week 48, 90% of patients achieved HiSCR, with 90% meeting the IHS4-55 threshold and 60% reaching the NRS30 criteria. Faster responses were recorded in subjects with Hurley stage II, treatment delays of <10 years, or no prior biologics use, although response rates equalized by week 48. All patients, particularly moderate cases, either discontinued or transitioned to monotherapy with systemic antibiotics. Conclusions: Secukinumab demonstrated efficacy in alleviating HS symptoms in moderate-to-severe cases. Patients with less severe disease, shorter treatment delays, and/or no prior biologic therapy exhibited more rapid initial responses. Additionally, the majority of patients experienced a significant duration of antibiotic cessation, underscoring the importance of early intervention. Future studies with larger populations are required to substantiate these findings.-
dc.language영어-
dc.publisherMATTIOLI 1885-
dc.relation.isPartOfDERMATOLOGY PRACTICAL & CONCEPTUAL-
dc.titleSecukinumab Efficacy Predictors in Korean Hidradenitis Suppurativa: A 48-Week Clinical Trial Analysis-
dc.typeArticle-
dc.contributor.googleauthorHa Nguyen, Ngoc-
dc.contributor.googleauthorLee, Sang Gyu-
dc.contributor.googleauthorHam, Seoyoon-
dc.contributor.googleauthorLee, Ju Hee-
dc.contributor.googleauthorLee, Young In-
dc.identifier.doi10.5826/dpc.1504a5933-
dc.identifier.pmid41236246-
dc.subject.keywordHidradenitis Suppurativa-
dc.subject.keywordSecukinumab-
dc.subject.keywordKorean Patients-
dc.subject.keywordPredictive Factors-
dc.subject.keywordIHS4-55-
dc.contributor.affiliatedAuthorHa Nguyen, Ngoc-
dc.contributor.affiliatedAuthorLee, Sang Gyu-
dc.contributor.affiliatedAuthorHam, Seoyoon-
dc.contributor.affiliatedAuthorLee, Ju Hee-
dc.contributor.affiliatedAuthorLee, Young In-
dc.identifier.scopusid2-s2.0-105023102399-
dc.identifier.wosid001614960200029-
dc.citation.volume15-
dc.citation.number4-
dc.identifier.bibliographicCitationDERMATOLOGY PRACTICAL & CONCEPTUAL, Vol.15(4), 2025-10-
dc.identifier.rimsid90464-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorHidradenitis Suppurativa-
dc.subject.keywordAuthorSecukinumab-
dc.subject.keywordAuthorKorean Patients-
dc.subject.keywordAuthorPredictive Factors-
dc.subject.keywordAuthorIHS4-55-
dc.subject.keywordPlusMULTICENTER-
dc.subject.keywordPlusADALIMUMAB-
dc.subject.keywordPlusSUNSHINE-
dc.subject.keywordPlusSAFETY-
dc.type.docTypeArticle-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryDermatology-
dc.relation.journalResearchAreaDermatology-
dc.identifier.articlenoe20255933-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.